Advertisement
Advertisement
U.S. Markets closed
S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 657.15 |
| Open | 661.29 |
| Bid | 645.63 x 800 |
| Ask | 662.89 x 800 |
| Day's Range | 647.54 - 664.85 |
| 52 Week Range | 492.13 - 747.42 |
| Volume | |
| Avg. Volume | 647,442 |
| Market Cap | 71.101B |
| Beta (5Y Monthly) | 0.21 |
| PE Ratio (TTM) | 10.57 |
| EPS (TTM) | 62.53 |
| Earnings Date | Feb 03, 2022 - Feb 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 702.05 |
- Zacks
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
- Zacks
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
- Zacks
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
